Transplant-Eligible Newly Diagnosed Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Tailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma.
High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma. This option is usually offered to patients less than 70 years old who have no major comorbidities. Selected older patients and those with mild to moderate organ dysfunction may also be reasonable candidates. An impo...
متن کاملInduction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials
OBJECTIVE The aim of this study was to compare the early efficacy and survivals of induction regimens for transplant-eligible patients with untreated multiple myeloma. MATERIALS AND METHODS A comprehensive literature search in electronic databases was conducted for relevant randomized controlled trials (RCTs). Eligible studies were selected according to the predefined selection criteria, befo...
متن کاملBest practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.
No survival advantage of autologous stem cell transplantation (ASCT) has been documented for patients older than 65 years, and in the era of thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid), ASCT has a diminished role in the front-line treatment of older patients with myeloma. For these individuals and for those who cannot or choose not to undergo ASCT, the initial trea...
متن کاملReview of 1027 patients with newly diagnosed multiple myeloma.
OBJECTIVE To determine the clinical and laboratory features of newly diagnosed multiple myeloma. PATIENTS AND METHODS Records of all patients in whom multiple myeloma was initially diagnosed at the Mayo Clinic in Rochester, Minn, from January 1, 1985, to December 31, 1998, were reviewed. RESULTS Of the 1027 study patients, 2% were younger than 40 years, and 38% were 70 years or older. The m...
متن کاملContinuous lenalidomide treatment for newly diagnosed multiple myeloma.
BACKGROUND Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed mu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2019
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000615300.45118.b2